SH3-domain mutations selectively disrupt Csk homodimerization or PTPN22 binding.

Area of Science:

• Biochemistry
• Cell Biology
• Immunology

Background:

• The kinase Csk is a key negative regulator of Src-family kinases (SFKs).
• Csk phosphorylates SFKs to mediate autoinhibition and binds phosphatases like PTPN12 and PTPN22.
• Csk function is enhanced by Csk-binding proteins that promote oligomerization and high local concentration.

Purpose of the Study:

• To investigate Csk homodimerization in T cells and its competition with PTPN22 binding.
• To design and validate Csk mutants that selectively disrupt homodimerization or PTPN22 interaction.
• To assess the impact of impaired Csk homodimerization or PTPN22 binding on Csk's negative regulatory function.

Main Methods:

• Site-directed mutagenesis of Csk SH3 domain to create H21I (impairs homodimerization) and K43D (impairs PTPN22 binding) mutants.
• In vitro kinase assays to verify the activity of purified Csk mutants.
• Cellular assays using Jurkat T cells to assess the functional consequences of disrupting Csk homodimerization and PTPN22 binding.

Main Results:

• Csk homodimerization occurs in Jurkat T cells and competes with PTPN22 binding.
• Csk mutants H21I and K43D selectively impaired homodimerization and PTPN22 binding, respectively, while retaining kinase activity.
• Disruption of either Csk homodimerization or PTPN22 interaction in cells reduced Csk's negative regulatory function.
• Csk mutant W47A showed impaired PTPN22 binding and secondary impairment of homodimerization.

Conclusions:

• Csk homodimerization and PTPN22 binding are critical for its function as a negative regulator of SFKs in T cells.
• The designed Csk mutants (H21I, K43D) are valuable tools for studying SFK regulation and autoimmunity.
• Further research into Csk homodimer activity and phosphatase interactions may uncover novel regulatory mechanisms in various cell types.